<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H90FAD15FB1F144CC844BB2E803EDC21A" public-private="public" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 639 IH: Improving Regulatory Transparency for New Medical Therapies Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-02-02</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code> 
<congress>114th CONGRESS</congress>
<session>1st Session</session>
<legis-num>H. R. 639</legis-num> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20150202">February 2, 2015</action-date> 
<action-desc><sponsor name-id="P000373">Mr. Pitts</sponsor> (for himself, <cosponsor name-id="P000034">Mr. Pallone</cosponsor>, and <cosponsor name-id="G000410">Mr. Gene Green of Texas</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on the <committee-name committee-id="HJU00">Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc>
</action> 
<legis-type>A BILL</legis-type> 
<official-title>To amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing.</official-title> 
</form> 
<legis-body id="H9F888CE5C0CA4E8DB20B9231C45BAB3C" style="OLC"> 
<section id="H5C67AA1A046142359BE20979A146CBF2" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Improving Regulatory Transparency for New Medical Therapies Act</short-title></quote>.</text></section> <section id="H04DCC452F6484184B529607A5ED5A904"><enum>2.</enum><header>Scheduling of substances included in new FDA-approved drugs</header><text display-inline="no-display-inline">Section 201(a) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/811">21 U.S.C. 811(a)</external-xref>) is amended by adding at the end the following: <quote>Any such proceedings initiated at the request of the Secretary under this subsection to control a drug or other substance not previously scheduled, where the Secretary has recommended the drug or other substance be placed in schedule II, III, IV, or V, shall be commenced not later than 120 days after receipt of written recommendations from the Secretary. The final rule shall be issued not later than 60 days after the date on which both the public comment period has closed and the drug or other substance is the subject of an approved new drug application under section 505 of the Federal Food, Drug, and Cosmetic Act, unless a hearing on the proposed rule is granted by the Attorney General.</quote>.</text></section> 
<section id="HB135390E6EF44B8C9C5A707CA84CAD2B"><enum>3.</enum><header>Enhancing new drug development</header><text display-inline="no-display-inline">Section 303 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823</external-xref>) is amended by adding at the end the following:</text> <quoted-block style="OLC" id="HC7BF2F190F9B44F884629FEC7BBB9768" display-inline="no-display-inline"> <subsection id="H28B054164D2344DA918FAE84AF17CA59"><enum>(i)</enum> <paragraph id="HA9CD2936791645F5822A9895CEACC4B4" display-inline="yes-display-inline"><enum>(1)</enum><text display-inline="yes-display-inline">For the purposes of registration to manufacture a controlled substance under subsection (d) of this section for use only in a clinical trial, the Attorney General shall register an applicant or serve an order to show cause upon an applicant pursuant to section 304(c) of this Act not later than 180 days after receipt of an application and all information the Attorney General deems necessary to make a determination under subsection (d).</text></paragraph> 
<paragraph id="H0FE32C4382984DDDB0545D8B8E515686" indent="up1"><enum>(2)</enum><text display-inline="yes-display-inline">For the purposes of registration to manufacture a controlled substance under subsection (a) for use only in a clinical trial, the Attorney General shall, in accordance with regulations issued by the Attorney General, issue a notice of application not later than 90 days after receipt of an application and all information the Attorney General deems necessary to issue a notice of application. Following the close of the comment period and receipt of all information the Attorney General deems necessary to make a determination under subsection (a), the Attorney General shall register an applicant or serve an order to show cause upon an applicant pursuant to section 304(c) of this Act within 180 days, unless a hearing on the application has been granted by the Attorney General pursuant to section 1008(i) of the Controlled Substances Import and Export Act. </text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section> </legis-body> </bill> 

